Recordati CEO sees ‘substantial opportunity’ in Sanofi drug purchase
Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company’s purchase of Sanofi’s rare immune disorder drug, Enjaymo.
Share
Rob Koremans, CEO of Italian pharmaceutical company Recordati, weighs in on the company’s purchase of Sanofi’s rare immune disorder drug, Enjaymo.
Watch the opening bell for the New York Stock Exchange and the Nasdaq from November 13, 2024 Source link
Coinbase CEO Brian Armstrong joins “Squawk Box’ to discuss crypto’s post-election rally, impact of President-elect Trump’s victory on the industry, launch of the ‘Coinbase 50 Index’, crypto’s role in the 2024 election, and more. Source link
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Courtney Garcia, Payne Capital Management senior wealth advisor, joins CNBC’s ‘Closing Bell’ to discuss whether investors should keep buying into the post-election surge, what sectors to keep an eye on, and more. 04:25 Wed, Nov 13 20244:13 PM EST Source link
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Mark Hawtin, head of global equities at Liontrust Asset Management, said Elon Musk’s goals to achieve a $2 trillion reduction in the U.S. government’s annual budget will be “unachievable.” Source link
CNBC’s David Faber joins ‘Squawk on the Street’ with Liberty Media Chairman John Malone. Source link
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Adrian Mucalov from Actis talks about where the infrastructure investment firm is positioned, why sustainability in data centers is a key concern, and other opportunities in Asia. Source link